A national education program for pharmacists funded by the Australian Government under the Quality Use of Diagnostics, Therapeutics and Pathology program.[/caption]
While the evidence bases for both CMs and Schedule 3 sleep aids are unlikely to immediately change, a core practice consideration is the risk-benefit profile of the respective non-prescription sleep aids for the individual patient. 
Is it really insomnia?
Knowledge to practice 
Budget’s funding welcome, but more is needed for pharmacy
PSA has welcomed the government’s commitment to pharmacy in the 2019-20 Federal Budget through the extension of the Administration Handling and Infrastructure (AHI) fee...
Blockchain exec pushing for the end of paper prescriptions
Australian laws requiring use of paper documents prevent new technological solutions that could inhibit prescription fraud.
That’s the diagnosis of Dr Tal Rapke, chief executive...
Help patients beat the extreme heat
Australia is in the midst of a record-breaking heatwave – with Western Australia, South Australia, Tasmania, Victoria, the ACT and NSW all reaching maximum...
Medicine safety: The big picture
Dr Libby Roughead MPS is Senior Principal Research Fellow at the University of South Australia’s School of Pharmacy, where her work focuses on quantifying...
New ECP Director to focus on the future
WA-based hospital pharmacist Lauren Burton has been appointed as the new Early Career Pharmacist (ECP) Director of PSA, effective from 1 July 2018.
PSA...
Australian pharmacists get seat at global table
The international voice of Australian pharmacy has been amplified by the appointment of PSA National President Dr Shane Jackson to the International Pharmacy Federation...
